DEPRESSION THERAPEUTICS MARKET ANALYSIS

Regional Analysis

Global Depression Therapeutics Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global depression therapeutics market over the forecast period. North America is estimated to hold 33.5% of the market share in 2023. The global depression therapeutics market is expected to witness significant growth in the coming years, driven by the high prevalence of mental health disorders, favorable health reimbursement, and increased awareness. Increasing drug approvals by regulatory bodies  is contributing to the growth of the depression therapeutics market in the North America region. For instance, in August 2020, The Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for SPRAVATO (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior. SPRAVATO is the first and only approved medicine that has been shown to reduce depressive symptoms within 24 hours, providing a new option for significant symptom relief until a longer-term, comprehensive treatment plan can take effect.

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Middle East: GCC, Israel, and Rest of Middle East
• Africa: South Africa, North Africa, and Central Africa